No psychedelic substance is rescheduled from Schedule I to Schedule II or III in the United States before January 1, 2029

DEA rescheduling requires a formal rule-making process including FDA scheduling recommendation, DEA initiation, public comment period (minimum 60 days), and final rule publication. This process has historically taken 3–7 years even after FDA approval. MDMA's CRL in 2024 and psilocybin's lack of NDA filing mean no candidate is close enough to trigger the process. Executive orders cannot bypass the Controlled Substances Act's statutory requirements. No psychedelic has completed this process in under three years from NDA approval. Confidence adjusted slightly down from 0.80 to 0.77 to account for low-probability fast-track scenarios under political pressure.